Ricevi le ultime notizie sulle azioni Unicycive Therapeutics con aggiornamenti su tendenze di mercato, dati finanziari e analisi di Benzinga. Rimani informato sulle performance di UNCY

Ultime notizie per

UNICYCIVE THERAPEUTICS INC

Unicycive Therapeutics

Unicycive Therapeutics Inc is a biotechnology company dedicated to developing treatments for certain medical conditions. It is focusing on kidney diseases. The company's manufactures drug, Renazorb, is a novel phosphate-binding agent being developed for the treatment of hyperphosphatemia. Unicycive's other drug, UNI-494, is a new chemical entity with the issued composition of matter patent protection in late preclinical development for the treatment of acute kidney injury. Company's pipeline comprised of two product candidates: Oxylanthanum Carbonate and UNI-494.

Unicycive Therapeutics, Inc. - Common Stock

Unicycive Therapeutics Inc

News

Legal

Press Releases

ROSEN, A RANKED AND LEADING LAW FIRM, Encourages Unicycive Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Fraud Lawsuit – UNCY

Investors who lost money on Unicycive Therapeutics, Inc.(UNCY) should contact Levi & Korsinsky about pending Class Action - UNCY

Unicycive Therapeutics, Inc. Class Action: Levi & Korsinsky Reminds Unicycive Therapeutics, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of October 14, 2025 – UNCY

Unicycive Therapeutics, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - UNCY

Penny Stocks

UNCY Investors Have Opportunity to Lead Unicycive Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm

Pomerantz Law Firm Announces the Filing of a Class Action Against Unicycive Therapeutics, Inc. and Certain Officers - UNCY

SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Unicycive

UNICYCIVE LAWSUIT ALERT: Bragar Eagel & Squire, P.C. Reminds Investors in Unicycive to Contact the Firm Regarding Filed Class Action Lawsuit Before October 14th

ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Unicycive Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Fraud Lawsuit – UNCY

UNCY Investors have Opportunity to Lead Unicycive Therapeutics, Inc. Securities Fraud Lawsuit

UNCY

Adagene Inc. - ADS, each representing 1.25 ordinary shares

Adagene

Artiva Biotherapeutics, Inc. - Common Stock

Artiva Biotherapeutics

Alterity Therapeutics Limited - American Depositary Shares

Alterity Therapeutics

Burning Rock Biotech Limited - American Depositary Shares

Burning Rock Biotech

Cibus

Clene

Connect Biopharma Holdings Limited - Ordinary Shares

Connect Biopharma Hldgs

Coeptis Therapeutics Holdings, Inc. - Common Stock

Coeptis Therapeutics

Entera Bio

Fortress Biotech

Werewolf Therapeutics, Inc. - Common Stock

Werewolf Therapeutics

InflaRx

Immunic

Metagenomi

NewAmsterdam Pharma Company N.V. - Warrant

NewAmsterdam Pharma Co

OKYO Pharma

PMV Pharma

Prelude Therapeutics Incorporated - Common Stock

Prelude Therapeutics

Pelthos Therapeutics

Quince Therapeutics

Repare Therapeutics

Sutro Biopharma

Whitehawk Therapeutics, Inc. - Common Stock

Comments

Unicycive Therapeutics Notizie sulle azioni

Notizie

Ultime notizie per

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO